CD4+ T-cell Reprogramming for Anti-tumor Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in effectively targeting and silencing tumor-specific regulatory T-cells to enhance anti-tumor immune responses while avoiding suppression of cancer-fighting immune responses.
Innovation Solution
A method involving the use of retinoic acid, TGF-β, and IL-27 to reprogram CD4+ T-cells into tumor-specific cytotoxic T-cells, which express CD8αα and are characterized by downregulation of ThPOK, Gata3, and upregulation of Runx3 and Tbet, allowing for targeted anti-tumor activity without suppression by regulatory T-cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If regulatory T-cells are present in the tumor environment, then immune tolerance is maintained and self-reactivity is prevented, but anti-tumor immune responses are suppressed
Solution Approach 1:
The patent extracts and eliminates regulatory T-cells from the tumor environment through specific depletion strategies, removing the suppressive element while preserving anti-tumor immunity. This involves identifying and selectively removing T-regs that inhibit cancer-fighting responses.
Solution Approach 2:
The patent changes the functional parameters of CD4+ T-cells by inducing them to acquire cytotoxic capabilities through exposure to specific cytokines and signaling pathways, transforming them from regulatory/suppressive phenotypes into effector/cytotoxic phenotypes that can kill tumor cells.
2Productivity
If tumor-specific T-regs are targeted and silenced to enhance anti-tumor responses, then cancer-fighting immunity is improved, but safety concerns and targeting challenges arise
Solution Approach 1:
The patent applies local quality by directing cytotoxic activity specifically at tumor cells through antigen-specific T-cells rather than globally suppressing all regulatory T-cells. This involves using tumor-specific antigens to guide the cytotoxic response to the tumor microenvironment while sparing other tissues.
Solution Approach 2:
The patent uses chimeric antigen receptors (CARs) as intermediaries that bridge the recognition of tumor antigens and the activation of cytotoxic T-cell functions. These engineered receptors serve as mediators that enable precise targeting of tumor cells while maintaining safety through controlled activation.
3Productivity
If CD4+ T-cells are reprogrammed to express CD8αα and acquire cytotoxic function, then tumor-targeting capability is enhanced, but cell differentiation complexity increases
Solution Approach 1:
The patent merges functions by combining CD4+ T-cell antigen recognition capabilities with CD8αα-mediated cytotoxic killing functions into a single cell type. This creates hybrid CD4+ cytotoxic T-cells that can both recognize tumor antigens via TCR and execute killing through perforin/granzyme pathways typically associated with CD8+ cells.
Solution Approach 2:
The patent creates multi-functional T-cells that can perform both regulatory/suppressive functions and cytotoxic killing functions depending on activation context. The reprogrammed CD4+ T-cells maintain versatility by being able to respond to different signals and perform different functions as needed.
Data Source
AI summary
The present disclosure relates to particular subsets of CD4+ and CD8+ T-cells, methods of isolating and generating these cells, compositions comprising these cells, and methods of treatment of a tumor or cancer by administering these cells alone or in combination with each other and/or additional therapies.